Immunic (NASDAQ:IMUX) Upgraded by Leerink Partnrs to Strong-Buy

Leerink Partnrs upgraded shares of Immunic (NASDAQ:IMUX) to a strong-buy rating in a research report sent to investors on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Immunic’s Q3 2024 earnings at ($0.22) EPS, Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.41) EPS.

A number of other research analysts have also commented on the company. Leerink Partners restated an outperform rating and issued a $5.00 target price on shares of Immunic in a research note on Monday. StockNews.com upgraded Immunic from a sell rating to a hold rating in a research report on Tuesday, August 13th. B. Riley started coverage on Immunic in a report on Tuesday, August 27th. They set a buy rating and a $6.00 target price on the stock. Finally, Piper Sandler reaffirmed an overweight rating and issued a $28.00 price target on shares of Immunic in a report on Tuesday, July 16th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of Buy and a consensus price target of $11.20.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $1.49 on Monday. Immunic has a 52-week low of $0.95 and a 52-week high of $1.92. The company has a market cap of $134.22 million, a P/E ratio of -0.81 and a beta of 1.82. The stock’s 50-day moving average is $1.39 and its 200-day moving average is $1.31.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same quarter last year, the company posted ($0.54) earnings per share. As a group, equities analysts predict that Immunic will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Immunic during the 1st quarter worth $9,266,000. Sierra Summit Advisors LLC bought a new stake in shares of Immunic during the 4th quarter valued at $487,000. Ikarian Capital LLC lifted its stake in shares of Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Immunic in the 1st quarter valued at $25,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.